相关临床试验
90
30 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1999
进行中（未招募）
6
6.7%
已完成
29
32.2%
尚未招募
24
26.7%
招募中
22
24.4%
终止
6
6.7%
撤回
3
3.3%
暂无批准数据
- The TRIDENT trial demonstrated that GMRx2, a single-pill combination of three low-dose blood pressure medications, reduced recurrent stroke risk by 39% in patients with intracerebral hemorrhage. - The study involved 1,670 patients and showed that one stroke was prevented for every 35 patients treated with GMRx2 over an average 3-year follow-up period. - GMRx2 achieved superior blood pressure control with mean systolic blood pressure levels 9mmHg lower than placebo, while maintaining a comparable safety profile. - The triple combination pill, also known as Widaplik, received FDA approval in June as the first single-pill triple therapy for hypertension and is set to launch in Q4 2024.
- George Medicines has secured exclusive licensing agreements with Orient EuroPharma for Southeast Asia and Arrotex Pharmaceuticals for Australia and New Zealand to commercialize GMRx2, an innovative triple-combination hypertension therapy. - GMRx2 combines telmisartan, amlodipine, and indapamide in a single pill with three dosage options, including two lower-dose formulations designed to deliver triple therapy benefits early in treatment with established safety profiles. - The drug demonstrated significant blood pressure reduction and improved control rates in Phase III trials published in the Journal of the American College of Cardiology and The Lancet, with good tolerability and no increased treatment withdrawals. - These partnerships expand GMRx2's global footprint to include markets where hypertension control rates remain suboptimal, with only half of Australian patients and a quarter of New Zealand patients achieving effective blood pressure control.
- George Medicines announced positive results from the TRIDENT trial, showing GMRx2 significantly reduced recurrent stroke risk in patients with intracerebral hemorrhage history. - The multicenter, placebo-controlled trial represents the first stroke outcomes study using a low-dose triple combination therapy for blood pressure management in ICH survivors. - GMRx2 combines telmisartan, amlodipine, and indapamide in a single pill, addressing the critical unmet need for enhanced blood pressure control in high-risk stroke patients. - The results were presented at the World Stroke Congress 2025 in Barcelona, with full trial data to be submitted for peer-reviewed publication.
- The FDA has approved WIDAPLIK (telmisartan, amlodipine, and indapamide), marking the first and only triple-combination medication approved for initial hypertension treatment in adults. - Two Phase 3 trials demonstrated WIDAPLIK's superior blood pressure reduction compared to dual combinations and placebo, with good tolerability and safety profiles. - The single-pill combination addresses a critical unmet need, as nearly half of US adults have hypertension and only one in four achieve blood pressure control. - George Medicines plans to launch WIDAPLIK commercially in Q4 2025, potentially improving treatment adherence and outcomes for hypertension patients.
- Post-hoc analysis of ADVANCE trial reveals intensive glucose lowering reduced vascular events risk by 10% and cardiovascular death risk by 12% in type 2 diabetes patients. - Benefits of intensive glucose control were consistent across all patient subgroups, regardless of age at diagnosis or duration of diabetes. - While treatment showed significant benefits, researchers noted increased hypoglycemia risk across all subgroups, emphasizing need for careful therapy management.
- A Phase III clinical trial demonstrated that GMRx2, a triple combination pill, is significantly more effective than dual combinations in controlling blood pressure. - The trial, involving 1,385 patients across multiple countries, supports GMRx2's potential to transform hypertension management globally, pending regulatory approval. - GMRx2 combines telmisartan, amlodipine, and indapamide in varying doses, showing significant blood pressure reductions compared to placebo and standard care in separate studies. - The treatment demonstrated excellent safety and tolerability, addressing critical needs for more effective options to manage hypertension, which affects over 1.2 billion adults worldwide.
• A meta-analysis of 11 clinical trials reveals that GLP-1 receptor agonists significantly reduce the risk of kidney failure and worsening kidney function. • The study demonstrates a 16% reduction in kidney failure and a 22% reduction in the worsening of kidney function among patients treated with GLP-1s. • GLP-1 receptor agonists also showed a 14% reduction in cardiovascular events and a 13% reduction in all-cause mortality. • Researchers suggest GLP-1s could play a key role in kidney and heart-protective treatments for individuals with type 2 diabetes, obesity, or chronic kidney disease.
